Just before the Ag Media Summit started, Intervet/Schering-Plough Animal Health invited a group of journalists to attend a session on their new Onset 5 IN product. At the event I spoke with Dr. Scott Nordstrom, Intervet, about the first intranasally administered, five-way modified-live virus (MLV) vaccine for healthy cattle 3 to 8 days and older. He says that this product challenges traditional thinking that young calves can’t respond to treatment because they have an immature immune system.
Onset 5 IN is designed to stimulate at the site of infection an immune response to
Bovine Virus Diarrhea (BVD) Type 1 and Type 2, Infectious Bovine Rhinotracheitis (IBR), Parainfluenza3 (PI3) and Bovine Respiratory Syncytial Virus (BRSV) – the costliest diseases impacting beef and dairy herds.
“Onset 5 IN is changing the way the beef and dairy industries think about the immune development of calves and, subsequently, the ability to help beef and dairy calves get off to a strong immunological life,” says Dr. Scott Nordstrom, Manager of Veterinary Technical Services for Intervet.
He says, “The bovine fetus has a much more mature immune system than originally believed.1 In fact, the immune system of the fetus is functional at approximately 170 days of gestation. We’ve also learned that development of the immune system is independent of antibody production, meaning the immune system can respond to an appropriately-delivered vaccine without antibody interference. This knowledge underpins the developmental science of Onset 5 IN and is why the intranasal route of administration of Onset 5 IN is so important.”
You can listen to my interview with Scott here: ams-08-nordstrom.mp3
Ag Media Summit Photo Album
AgWired coverage of the Agricultural Media Summit is sponsored by:
and 